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ontrast-enhanced ultrasound is used effectively throughout the world, espe-
cially in the diagnosis and characterization of focal liver lesions. Currently,
heart chamber opacification and delineation of endocardial borders are the
only clinical applications approved by the US Food and Drug Administration
(FDA). As a result, contrast-enhanced ultrasound use in the United States lags behind
the rest of the world and has yet to become approved by the FDA for a broad range of
applications that are currently available and contributing valuable diagnostic and
management information in other countries. The lack of ultrasound contrast availabil-
ity potentially hinders the delivery of optimal diagnostic imaging, resulting in an
adverse impact on clinical care to our society.
Under the leadership of Lennard Greenbaum, MD, immediate past president of the
American Institute of Ultrasound in Medicine (AIUM), a dialog has been established
with the FDA to encourage the review and approval for clinical use of ultrasound con-
trast agents. To enhance the exchange of information among interested groups, a series
of educational seminars have been presented to the FDA over the past year. At the
request of the FDA, the AIUM wrote a protocol for the performance of clinical trials,
“American Institute of Ultrasound in Medicine Recommendations for Contrast-
Enhanced Liver Ultrasound Imaging Clinical Trials,” which appears in this issue of the
Journal of Ultrasound in Medicine (JUM), to facilitate increasing awareness of design-
ing proper clinical trials.
This document and the joint sessions
have been well received, with the result
that the FDA has requested recommenda-
tions for ultrasound contrast agent clinical
trials as a step toward approval of broader
clinical applications. Initial focus will be
on the liver, with other organs and appli-
cations to follow, with the goal of decreas-
ing variance among clinical sites and
increasing the likelihood of successful
clinical trials. These trials should help
establish clinical efficacy in addition to
standardizing clinical protocols to ensure
that high-quality studies are performed at
all sites.
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“The lack of ultrasound
contrast availability
potentially hinders the
delivery of optimal 
diagnostic imaging,
resulting in an adverse
impact on clinical care
to our society.”
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Meanwhile, the clinical use of contrast agents
continues to expand worldwide. As experience is
gained, there has been a growing recognition and
appreciation that standardization of concepts
and terminology is essential to further facilitate
clinical use of ultrasound contrast agents and
exchange information.
This issue of the JUM includes a Special Report,
“Terminology for Contrast-Enhanced Sonography:
A Practical Glossary,” by Catalano and colleagues
from the Ultrasound Section of the Italian
Association of Medical Radiology. The glossary is
indicative of the scope and maturity of contrast-
enhanced ultrasound clinical applications in the
global community.
We at the JUM strongly support and encourage
endeavors working toward more rapid approval
of ultrasound contrast agent clinical applications
as part of continuing improvements in providing
optimal diagnostic imaging and patient care.
Under the leadership of the FDA, the AIUM, and
other interested parties, the JUM and the AIUM
look forward to successful approval of ultra-
sound contrast agents for clinical use in the
United States in the near future. 
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“We at the JUM strongly support
and encourage endeavors working
toward more rapid approval of
ultrasound contrast agent clinical
applications as part of continuing
improvements in providing optimal
diagnostic imaging and patient
care.”
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